fps-zm1 alleviates circulating indices of liver injury in diet-induced type 2 diabetic mice

Despite dietary/lifestyle modifications as well as glycemic and lipid control, non-alcoholic fatty liver disease (nafld) imposes a considerable risk to the patients by advancing to non-alcoholic steatohepatitis (nash). the present investigation aims to evaluate the protective potential of fps-zm1, a selective inhibitor for advanced glycation end products (rage), against circulating indices of liver injury in high fat diet-induced diabetic mice. fps-zm1 at 0.5. 1, and 2 mg/kg (orally) was administered for 2 months, starting 4 months after provision of the high-fat diet. tests for glucose homeostasis, liver injury markers, and hepatic/plasma mir-21 expressions were performed. fps-zm1 attenuated diabetes-induced elevations in serum levels of alanine aminotransferase (alt), aspartate aminotransferase (ast), glutamate dehydrogenase (gld), and alpha glutathione-s-transferase (α-gst) as well as alkaline phosphatase (alp) and gamma-glutamyl transpeptidase (ggt). it also decreased diabetes-associated elevations in serum ferritin and plasma cytokeratin 18 fragments. additionally, fps-zm1 down-regulated elevated expressions of mir-21 in the liver and plasma of diabetic mice. these findings highlight the benefits of fps-zm in alleviating liver injury in mice evoked by high-fat diet-induced type 2 diabetes and suggest fps-zm1 as a new potential adjunct to the conventional diet/lifestyle modification and glycemic control in diabetics.